
Imatinib Mesylate
Form: Tablet
Strength: 50 mg, 100 mg, 400 mg
Reference Brands: Gleevec® (EU & US)
Category: Oncology Cancer Care
Imatinib Mesylate is a targeted therapy used in oncology to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), and other cancers. Available under the brand Gleevec® by Novartis and as generics, Imatinib is an essential tyrosine kinase inhibitor (TKI) used in cancer centers, hospitals, and oncology clinics. It blocks the action of abnormal proteins that contribute to cancer cell growth, making it crucial for effective cancer management. Available in oral tablets and generics, Imatinib Mesylate is widely sourced by B2B pharmaceutical wholesalers in the US and EU, ensuring reliable supply and GMP-compliant distribution for cancer treatment.
Quick Response Guaranteed | Verified Suppliers
Back to ListingThe Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View DetailsDurvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View DetailsSunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers